AI Article Synopsis
- Coccidioidomycosis can lead to serious meningitis, which needs long-term treatment.
- A study examined how pharmacogenomic testing (analyzing genetic variations) could impact treatment outcomes for patients with coccidioidal meningitis.
- Out of 13 patients tested, 11 had genetic variants that influenced antifungal effectiveness, resulting in immediate treatment adjustments and showing that such testing can prevent ineffective or harmful treatments.
Article Abstract
Coccidioidomycosis can cause severe meningitis, requiring lifelong treatment. In this study, we sought to better understand the potential effect of pharmacogenomic testing on treatment outcomes of patients with coccidioidal meningitis. Of 13 patients with coccidioidal meningitis who underwent pharmacogenomic testing, 11 had genetic variants of CYP2C19 and CYP3A5 that affect antifungal efficacy. These results led to real-time treatment changes and future antifungal planning. Routine pharmacogenomic testing helps to avoid antifungal treatments that are futile or lead to adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/mmy/myae113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of pharmacogenomic testing in optimizing depression treatment in medically underserved communities: Implications for nurse practitioner practice.
J Am Assoc Nurse Pract
December 2024
College of Graduate Nursing, Western University of Health Sciences, Pomona, California.
Depression is a leading cause of disability worldwide, with treatment-resistant depression (TRD) affecting approximately 30% of patients who do not respond to standard antidepressants. In underserved and uninsured communities, where Nurse Practitioners (NPs) often provide essential mental health care, the challenges of managing TRD are compounded by limited access to specialized services. Pharmacogenomic testing offers a promising approach to overcoming these barriers by providing personalized medication recommendations based on a patient's genetic profile.
View Article and Find Full Text PDFEffects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder.
Front Pharmacol
November 2024
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Background: In the treatment of depression, medication plays a crucial role. However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression, and consequently imposing a greater economic burden on the healthcare system.
Objectives: Our objective was to examine the impact of pharmacogenomic testing on medication adherence and antidepressant switching rates among individuals diagnosed with depression.
Pharmacogenomic variation and sedation outcomes during early intensive care unit admission: A pragmatic study.
Clin Transl Sci
December 2024
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
Unpredicted responses to sedatives and analgesics are common in critically ill patients on mechanical ventilation (MV) and may be attributed to genetic variation. Our primary aim was to investigate the association between the pharmacogenomic (PGx) variation and sedation outcomes. The secondary aim was to capture intensive care unit (ICU) participants' perceptions of PGx.
View Article and Find Full Text PDFClinical implementation of preemptive pharmacogenomics testing for personalized medicine at an academic medical center.
J Am Med Inform Assoc
December 2024
University of California, San Francisco, San Francisco, CA 94143, United States.
Objective: This article describes the implementation of preemptive clinical pharmacogenomics (PGx) testing linked to an automated clinical decision support (CDS) system delivering actionable PGx information to clinicians at the point of care at UCSF Health, a large Academic Medical Center.
Methods: A multidisciplinary team developed the strategic vision for the PGx program. Drug-gene interactions of interest were compiled, and actionable alleles identified.
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
JAMA Netw Open
December 2024
Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!